Edition:
United States

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

13.05USD
3:59pm EST
Change (% chg)

$0.07 (+0.54%)
Prev Close
$12.98
Open
$13.03
Day's High
$13.25
Day's Low
$12.95
Volume
342,086
Avg. Vol
800,512
52-wk High
$16.60
52-wk Low
$4.41

Select another date:

Wed, Nov 8 2017

BRIEF-Amicus Therapeutics Q3 loss per share $0.69

* Amicus therapeutics announces third quarter 2017 financial results and corporate updates

Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

BELGRADE Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

UPDATE 1-Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

BELGRADE, Oct 4 Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

BELGRADE, Oct 4 Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

BRIEF-Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society

* Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society

BRIEF-U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease

* U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease

BRIEF-Amicus Therapeutics announces approval for Galafold™ for treatment of Fabry disease in Canada

* Amicus Therapeutics Inc announces approval for Galafold™ (Migalastat) for treatment of Fabry disease in Canada

Amicus abandons wound treatment, focus shifts to future trial data

Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer's expanding pipeline.

UPDATE 3-Amicus abandons wound treatment, focus shifts to future trial data

* Analysts express optimism about upcoming trial data (Updates share price, adds analyst comment)

Amicus Therapeutics' wound treatment fails late-stage trial

Sept 13 U.S. drug developer Amicus Therapeutics Inc said on Wednesday its drug to treat wounds failed to meet the main goals of a late-stage clinical trial.

Select another date: